<DOC>
	<DOCNO>NCT00462709</DOCNO>
	<brief_summary>The study objective evaluate safety efficacy prophylactic use C1INH-nf prevention acute HAE attack .</brief_summary>
	<brief_title>Open-Label C1 Esterase Inhibitor ( C1INH-nf ) Prevention Acute Hereditary Angioedema ( HAE ) Attacks</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>History least 1 HAE attack per month history laryngeal edema In addition , study open subject : Completed participation LEVP20051/B ( NCT01005888 ) time final prophylactic therapy Part B Were enrol randomize LEVP20051/A ( NCT00289211 ) Part A close Were enrol randomize LEVP20051/A LEVP20051/B close enrollment , time 3day telephone followup Were exclude LEVP20051 follow reason : Pregnancy lactation Age le 6 year Narcotic addiction Presence antiC1 inhibitor ( C1INH ) autoantibody Were enrol LEVP20051 enrollment LEVP20051 close , follow circumstance : Had diagnosis HAE : evidence low C4 level plus either low C1INH antigenic level low C1INH functional level , Had know HAEcausing C1INH mutation , Had diagnosis HAE base strong family history HAE determine principal investigator History allergic reaction C1INH blood product Participated investigational drug study within past 30 day sponsor Lev Pharmaceuticals Received blood blood product past 60 day C1INHnf</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hereditary angioedema</keyword>
	<keyword>C1 esterase inhibitor ( human )</keyword>
</DOC>